16 reports

  • disorder acromegaly
  • presentation will focus on advancements in the current Phase II trial of ATL1103 for the growth disorder acromegaly

The drug candidate is based on antisense technology.

  • Antisense Technology
  • Therapy
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • Mar 10, 2017: Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting

As you know, DNAbilize& tradeis a proprietary antisense and neutral lipid technology that enables systemic delivery of nucleic acid therapeutics.

  • Antisense Technology
  • Therapy
  • United States
  • Company
  • Ogden Golf Co.
  • GP PHARM SA
  • presentation will focus on advancements in the current Phase II trial of ATL1103 for the growth disorder acromegaly

The drug candidate is based on antisense technology.

  • Antisense Technology
  • Hormone
  • Pharmaceutical
  • United States
  • Product Initiative
  • Deal in Brief
  • Advisor Information Company Being Advised

ISIS-SMNRx is based on antisense technology platform.

  • Antisense Technology
  • United States
  • Company
  • Company Financials
  • Ionis Pharmaceuticals, Inc.
  • PARTNERSHIPS
  • Antisense Therapeutics Completes Second Tranche Of Private Placement Of Common Stock For US$2.04 Million

The therapeutic candidate is developed based on antisense technology.

  • Antisense Technology
  • Pharmaceutical
  • Therapy
  • Australia
  • Antisense Therapeutics Limited
  • Feb 21, 2017: Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

As you know, DNAbilize& tradeis a proprietary antisense and neutral lipid technology that enables systemic delivery of nucleic acid therapeutics.

  • Antisense Technology
  • Therapy
  • United States
  • Company
  • Ogden Golf Co.

ISIS-SMNRx is based on antisense technology platform.

  • Antisense Technology
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • Biogen Idec Inc.
  • PIPELINE BY CAMBRYN BIOLOGICS LLC, H2 2019

It is developed based on antisense technology platform.

  • Antisense Technology
  • Therapy
  • United States
  • World
  • Product Initiative

RNAi therapeutics market, by technology, 2014 - 2025 (USD Million) TABLE ## U. S. antisense & RNAi therapeutics market, by application, 2014 - 2025 (USD Million) TABLE ## U. S. antisense & RNAi therapeutics market, by route of administration, 2014 - 2025 (USD Million)

  • Antisense Technology
  • Pharmaceutical
  • Therapy
  • United States
  • Market Size
  • PIPELINE BY GENZYME CORP, H2 2018

The company offers antisense technology based drugs that treats aggressive tumor diseases.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH

THE THERAPEUTIC CANDIDATE IS DEVELOPED BASED ON ANTISENSE TECHNOLOGY.

  • Antisense Technology
  • Cell Therapy
  • United States
  • Product Initiative
  • Sarepta Therapeutics, Inc.
  • PIPELINE BY NOVARTIS AG, H1 2017

The company offers antisense technology based drugs that treat aggressive tumor diseases.

  • Antisense Technology
  • Eye Disease
  • World
  • Product Initiative
  • Isarna Therapeutics GmbH

ISIS-SOD##Rx is based on antisense technology platform.

  • Antisense Technology
  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products

It is based on antisense technology platform.

  • Antisense Technology
  • Pharmaceutical
  • United States
  • Company Operations
  • Ionis Pharmaceuticals, Inc.
  • ATL-1101
  • ATL-1101 - DRUG PROFILE

The drug candidate is developed using antisense technology.

  • Antisense Technology
  • Insulin
  • Lung Cancer
  • United States
  • Product Initiative

The company offers antisense technology based drugs that treat aggressive tumor diseases.

  • Antisense Technology
  • Cell Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.